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Abstract. 
 
Animal cells divide into two daughter cells 
by the formation of an actomyosin-based contractile 
ring through a process called cytokinesis. Although 
many of the structural elements of cytokinesis have 
been identiﬁed, little is known about the signaling path-
ways and molecular mechanisms underlying this pro-
 
cess. Here we show that the human 
 
ECT2
 
 is involved in 
the regulation of cytokinesis. ECT2 catalyzes guanine 
nucleotide exchange on the small GTPases, RhoA, 
Rac1, and Cdc42. ECT2 is phosphorylated during G2 
and M phases, and phosphorylation is required for its 
exchange activity. Unlike other known guanine nucle-
otide exchange factors for Rho GTPases, ECT2 exhib-
its nuclear localization in interphase, spreads through-
out the cytoplasm in prometaphase, and is condensed in 
the midbody during cytokinesis. Expression of an ECT2 
 
derivative, containing the NH
 
2
 
-terminal domain re-
quired for the midbody localization but lacking the 
COOH-terminal catalytic domain, strongly inhibits cy-
tokinesis. Moreover, microinjection of afﬁnity-puriﬁed 
anti-ECT2 antibody into interphase cells also inhibits 
cytokinesis. These results suggest that ECT2 is an im-
portant link between the cell cycle machinery and Rho 
signaling pathways involved in the regulation of cell di-
vision.
Key words: cell division • phosphorylation • nucle-
otide exchange • oncogene • microinjection
 
C
 
ELLULAR
 
 division into two daughter cells occurs
through nuclear division and cytokinesis. In cyto-
kinesis, formation of an actomyosin-based con-
tractile ring separates the cytoplasm to two daughter cells.
A small GTPase RhoA appears to be localized in the
cleavage furrow during cytokinesis (Takaishi et al., 1995).
In lower eukaryotes, such as sand dollar,
 
 Dictyostelium
 
,
and 
 
Xenopus
 
, involvement of Rho GTPases in cell division
has been reported (Kishi et al., 1993; Mabuchi et al., 1993;
Larochelle, 1996; Drechsel et al., 1997). In 
 
Saccharomyces
cerevisiae
 
, cell division is achieved by budding, which is
controlled by Cdc42 (Chant and Pringle, 1991). In con-
trast, in mammalian cells, where Rho GTPases also regu-
late cell surface cytoskeletal organization, the role of Rho
GTPases in cell division is not well-documented.
The Rho family of small GTPases, represented by
RhoA, Rac1, and Cdc42, act as molecular switches of di-
verse biological functions involving cytoplasmic actin re-
modeling (Hall, 1998). The GTP-bound form of Rho pro-
teins is active, whereas the GDP-bound form is inactive.
Activation of the Rho proteins is promoted by guanine nu-
cleotide exchange factors (GEFs),
 
1
 
 which catalyze the re-
 
placement of bound guanosine diphosphate (GDP) by GTP.
The GTP-bound form of Rho proteins can specifically in-
teract with their effectors or targets and transmit signals
to downstream molecules. Rho proteins are inactivated
through the hydrolysis of bound GTP to GDP by intrinsic
GTPase activity, assisted by GTPase activating proteins
(GAPs). In fibroblasts, RhoA, Rac1, and Cdc42 regulate
formation of actin stress fibers, membrane ruffling, and
filopodia, respectively (Hall, 1998). The upstream stimuli
that regulate these GTPases are largely unknown, al-
though lysophosphatidic acid, PDGF, and Ras have been
shown to regulate the cytoskeletal changes controlled by
these GTPases (Hall, 1998).
We previously isolated the 
 
ect
 
2 oncogene in a search for
mitogenic signal transducers in epithelial cells, where a
murine keratinocyte expression cDNA library was intro-
duced into fibroblasts to induce foci of morphologically
transformed cells (Miki et al., 1991). Removal of the NH
 
2
 
-
terminal half of Ect2 strongly activates the transforming
activity of 
 
ect
 
2, and injection of 
 
ect
 
2 transfectants into
nude mice efficiently induces tumor formation. The cen-
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tral domain of Ect2 has sequence similarity with the 
 
dbl
 
oncogene (Miki et al., 1993), which has been shown to cat-
alyze guanine nucleotide exchange on the Rho family of
small GTPases (Hart et al., 1991). Ect2 associates with a
subset of the Rho family proteins: RhoA, RhoC, and Rac1
(Miki et al., 1993).
In this study, we show that human ECT2 catalyzes gua-
nine nucleotide exchange on Rho proteins. ECT2 is phos-
phorylated in a G2/M phase-specific manner, and phos-
phorylation is required for the exchange activity of ECT2.
In interphase cells, ECT2 is mainly localized in the nu-
cleus. However, in mitotic cells, ECT2 is localized pre-
dominantly in the midzone, where the formation of cleav-
age furrow starts. We found that the inhibition of ECT2 by
expression of a dominant negative mutant or microinjec-
tion of anti-ECT2 antibody specifically blocks the comple-
tion of cytokinesis, resulting in multinucleated cells.
 
Materials and Methods
 
Guanine Nucleotide Exchange Assays
 
The open reading frame of human ECT2 was introduced into the mamma-
lian expression vector pCEV32F3 (Lorenzi, et al., 1999) to express a
FLAG–ECT2 fusion protein. COS-7 cells were plated in 100-mm dishes
and transfected with 10 
 
m
 
g of plasmid DNA with Lipofectamine (GIBCO
BRL). Transfected cells were cultured for 48 h, harvested, and lysed in 1
ml of cold lysis buffer (25 mM Hepes, pH 7.5, 0.3 M NaCl, 1.5 mM MgCl
 
2
 
,
0.2 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 20 
 
m
 
g/ml
each of leupeptin and aprotinin, and 100 
 
m
 
g/ml PMSF). FLAG–ECT2 fu-
sion proteins were immunoprecipitated from the lysates with 9 
 
m
 
g/ml
of anti-FLAG mAb (Sigma Chemical Co.) and protein G–Sepharose
beads (Amersham Pharmacia Biotech). Guanine nucleotide exchange as-
says were performed essentially as described (Horii et al., 1994) using
these immunoprecipitates. In brief, 3 
 
m
 
g of GDP-loaded recombinant
GTPases were incubated with 5 
 
m
 
M [
 
35
 
S]GTP
 
g
 
S (0.25 mCi mmol
 
2
 
1
 
) and
10 
 
m
 
l of protein G beads suspension in 190 
 
m
 
l of exchange buffer (20 mM
Tris-HCl, pH 7.5, 10 mM MgCl
 
2, 
 
0.5 mM DTT, 100 mM NaCl, 0.5 mg/ml
BSA). At the indicated times, 30 
 
m
 
l of the reaction was removed and
passed through nitrocellulose filters. Filters were washed and then
counted in a liquid scintillation counter. For phosphatase treatment, im-
munoprecipitates were incubated with recombinant VHR protein (Ishi-
bashi et al., 1992)
 
 
 
or 
 
l
 
 phosphatase (New England Biolabs) for 30 min at
30
 
8
 
C, and then used for exchange assays.
 
Preparation of Anti-ECT2 Antibodies
 
GST–Ect2 fusion protein was expressed in 
 
Escherichia coli
 
 and used for
immunizing rabbits. The NH
 
2
 
-terminal half (ECT2-N; amino acids 1–421)
or Dbl homology domain (DH; amino acids 414–639) of human ECT2 was
expressed as fusion proteins with thioredoxine and oligohistidine using
the pET-32 vector (Novagen). Anti-ECT2 antibodies were prepared by
passing antiserum through affinity columns coupled with the correspond-
ing human ECT2 proteins using AminoLink Plus Immobilization Kit
(Pierce). Anti–ECT2-DH recognized a single ECT2 protein of 
 
z
 
100 kD.
Anti–ECT2-N also recognized the endogenous ECT2 protein, although
some additional bands were weakly detected.
 
Analysis of ECT2 Modification during Cell
Cycle Progression
 
HeLa cells were grown in DMEM (GIBCO BRL) supplemented with
10% FCS in 7% CO
 
2
 
 at 37
 
8
 
C. Cells were synchronized at the G1/S bound-
ary by a thymidine-aphidicolin double block (Golsteyn et al., 1995). In
brief, cells were incubated with 2 mM thymidine for 14 h, released from
arrest, and then arrested at G1/S again with aphidicolin (1 
 
m
 
g/ml) (Sigma
Chemical Co.). Cells were then placed under normal growth conditions
(time 0). After 6 h, nocodazole (final concentration 100 ng/ml) was added
to arrest the cells at prometaphase. Mitotic cells were collected by me-
chanical shake-off and replated in normal growth medium. Following
 
trypsinization, samples were analyzed by flow cytometry using FACS
 
®
 
 II
instrument (Becton Dickinson). For phosphatase treatment, G1 or M
phase arrested cells were lysed in TNE buffer (10 mM Tris-HCl, pH 7.8,
1% NP-40, 0.15 M NaCl, 1 mM EDTA pH 7.0, 10 
 
m
 
g/ml aprotinin) and in-
cubated with 1 
 
m
 
g/ml of recombinant VHR protein for 30 min at 30
 
8
 
C.
Samples were resolved by 6% SDS-PAGE, transferred to Immobilon-P
membranes (Millipore), and analyzed by immunoblotting using affinity-
purified anti-ECT2 antibodies.
 
Subcellular Localization of ECT2
 
To determine the localization of endogenous ECT2, HeLa cells were
grown on coverslips, fixed for 10 min with 3.7% formaldehyde in PBS,
permeabilized for 10 min with 0.2% Triton X-100 in PBS, and then incu-
bated with 1% BSA in PBS for 10 min. For costaining of endogenous
ECT2 and tubulin, coverslips were incubated with affinity-purified anti–
ECT2-DH antibody and anti–
 
b
 
-tubulin (TUB2.1; Sigma Chemical Co.)
mAbs for 1 h at 4
 
8
 
C. After washing, samples were incubated with FITC-
conjugated anti–rabbit IgG and Cy3-conjugated anti–mouse IgG (Jackson
ImmunoResearch, Inc.) for 1 h at room temperature. To express green
fluorescent protein (GFP)-fused ECT2 proteins in U2OS cells, ECT2-N,
ECT2-C, and ECT2-F were introduced into pEGFP-C1 (Clontech). After
transfection, cells were fixed and proteins visualized by green fluorescence
using a Zeiss Axiovert microscope equipped with a Photometrics digital
camera and IPLab software (Signal Analytics Co.).
 
Microinjection
 
HeLa cells were grown on poly-
 
L
 
-lysine–coated glass coverslips for 18–24 h
until the cultures reached 
 
z
 
50% confluency. The coverslips were trans-
ferred into fresh medium containing 10 mM Hepes, pH 7.6, before injec-
tion. Antibodies were dialyzed and concentrated to 1 mg/ml using a Cen-
tricon-30 concentrator (Amicon). Rabbit IgG (Sigma Chemical Co.) was
used as a control. Microinjection into the cytoplasm was performed using
Eppendorf semiautomatic microinjection apparatus. Immediately after in-
jection, coverslips were washed with PBS and incubated in growth me-
dium for the indicated time period. 
 
Results
 
ECT2 Is a GEF for RhoA, Rac1, and Cdc42
 
To examine the function of ECT2 as a Rho GEF, we ex-
pressed ECT2 as a FLAG epitope-tagged protein in COS
cells immunoprecipitated with anti-FLAG mAb, and used
immunoprecipitated protein for exchange assays. Full-
length ECT2 efficiently stimulated nucleotide exchange
on three representative members of the Rho GTPases,
RhoA, Rac1, and Cdc42 in vitro, whereas similar immuno-
precipitates from vector transfectants showed no signifi-
cant activity (Fig. 1 b, left panel). In contrast to the activity
on Rho GTPases, ECT2 did not exhibit significant ex-
change activity on two Ras family GTPases, H-Ras and
Rap1A (data not shown).
 
ECT2 Is Phosphorylated Specifically in G2 and
M Phases of the Cell Cycle
 
The predicted ECT2 protein also contains a novel domain
homologous to yeast S phase cyclin Clb6 (Schwob and
Nasmyth, 1993; Stuart and Wittenberg, 1998), and two tan-
dem repeats of the recently identified BRCA1 COOH-ter-
minal repeat (BRCT) motif (Fig. 1 a) that is widespread
throughout checkpoint and repair proteins (Saka et al.,
1994; Bork et al., 1997; Zhang et al., 1998). Since these
structural similarities suggest the possibility that ECT2 is
involved in cell cycle control, we examined in detail the ex-
pression pattern of ECT2 during the cell cycle. HeLa cells
were synchronized at the G1/S boundary, and the expres- 
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sion of ECT2 protein was examined by immunoblotting
after the release from G1 arrest. Although we did not ob-
serve significant changes in the overall expression level of
ECT2 protein during progression of the cell cycle, a shift
of the mobility of ECT2 was detected by anti-ECT2 anti-
body (Fig. 1 c, left panel). A slowly migrating protein ap-
peared at 9 h as cells entered G2 phase. At 14 h, as cells
entered M phase, the slowly migrating band predomi-
nated. The fraction of slowly migrating protein gradually
decreased as cells entered G1 phase (Fig. 1 c). To deter-
mine whether the shift of mobility of ECT2 was due to
protein phosphorylation, we treated M phase–arrested
cells with the tyrosine/serine/threonine phosphatase VHR.
No mobility shift was detected in M phase cells after VHR
treatment (Fig. 1 c, left panel). Therefore, ECT2 appeared
to be phosphorylated specifically at G2 phase, and this
state was manifested through M phase.
 
Phosphorylation Is Required for the Exchange Activity 
of ECT2
 
To further examine the effect of phosphorylation on the
exchange activity of ECT2, we treated FLAG–ECT2 im-
munoprecipitates with various concentrations of VHR. As
shown in the right panel of Fig. 1 b, the exchange activity
of ECT2 was inhibited by VHR in a dose-dependent man-
ner, and the incubation for 1 h with 0.5 
 
m
 
g/ml of VHR de-
creased the activity of FLAG–ECT2 to background levels.
Inhibition of exchange activity was also observed by treat-
ment of FLAG–ECT2 with 
 
l
 
 phosphatase, and this inhibi-
tory effect was strongly prevented by a phosphatase inhib-
itor vanadate (data not shown). These results suggest that
phosphorylation is required for the exchange activity of
ECT2 in vitro.
 
ECT2 Colocalizes with the Mitotic Spindle and Midbody 
in M Phase
 
Next, we examined the subcellular localization of endoge-
nous ECT2 during cell cycle progression by immunofluo-
rescent analysis of HeLa cells. Interestingly, in interphase
cells ECT2 was located predominantly in the nucleus,
where no expression of Rho family proteins has been re-
ported (Fig. 2 a). After nuclear membrane breakdown in
prometaphase, ECT2 spread into the cytoplasm (Fig. 2 b).
During metaphase, ECT2 accumulated in the regions
where the mitotic spindle is present (Fig. 2 c). Costaining
of ECT2 and tubulin generated the yellow colocalization
signal. As cells entered anaphase, ECT2 appeared to con-
centrate in the central region of the spindle (Fig. 2 d). In
late anaphase and telophase, ECT2 was mainly located in
the midzone, where the cleavage furrow is formed (Fig.
2 e). During cytokinesis, ECT2 accumulated at the mid-
body, a region in the middle of the bridge that connects
the two daughter cells (Fig. 2 f). When the cells exited mi-
tosis and the nuclear envelope reassembled, ECT2 translo-
cated to the nucleus again (data not shown). To locate the
region of ECT2 responsible for midbody localization, we
transfected cells with plasmids containing the NH
 
2
 
-termi-
nal half (ECT2-N), the COOH-terminal half (ECT2-C), or
full-length (ECT2-F) ECT2 as GFP fusion proteins. GFP
proteins were visualized 72 h after transfection (Fig. 3 A).
Like endogenous ECT2, GFP-tagged ECT2-F was de-
tected in the midbody of dividing cells. Although ECT2-N
localized in the cytoplasm of interphase cells (data not
shown), it accumulated in the midbody of dividing cells. In
contrast, ECT2-C was detected in the cytoplasm of mitotic
Figure 1. (a) Schematic representation of the human ECT2 pro-
tein. The human ECT2 cDNA clone was isolated from a B5/589
human epithelial cell cDNA library. The detailed structure will
be published elsewhere. CLB6, a domain homologous to a yeast
S phase cyclin CLB6. BRCT1 and BRCT2, BRCA1 COOH-termi-
nal repeats. DH, Dbl-homology domain. PH, pleckstrin-homol-
ogy domain. NLS, nuclear localization signals. The regions car-
ried by ECT2-F, ECT2-N, and ECT2-C are shown. (b) Guanine
nucleotide exchange activity of ECT2 on Rho GTPases. (Left
panel) Exchange activity of immunoprecipitates from FLAG-
ECT2–expressing cells (open symbols) or FLAG-expressing cells
(filled symbols) on RhoA (circles), Rac1 (squares), or Cdc42 (tri-
angles). Shown are representative results of at least three inde-
pendent experiments. (Right panel) FLAG-ECT2 immunopre-
cipitates were treated with the indicated concentrations (mg/ml)
of VHR at 308C for 1 h and then subjected to exchange assays on
Rac1. V, immunoprecipitates from vector alone-transfectants.
VHR-treated ECT2 immunoprecipitates did not show apparent
degradation. (c) G2/M-specific phosphorylation of ECT2. HeLa
cells were synchronized at G1/S boundary by thymidine/aphidi-
colin double block. ECT2 protein was detected with anti-ECT2
antibody in the cells as they progress through the cell cycle upon
release from the drug arrest (upper left panel). Lysates of cells
arrested at G1 phase by aphidicolin or at M phase by nocodazole
were incubated with a protein phosphatase VHR, separated by
SDS-PAGE, and analyzed for ECT2 (lower left panel). DNA
contents of the cells in the above samples were analyzed by flow
cytometry following the release from the G1 arrest (right panel).
Positions of cells in G1 phase (2N) and G2/M phase (4N) are
shown by arrowheads. 
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cells. These observations indicate that the NH
 
2
 
-terminal
half of ECT2 is required for midbody localization. The nu-
clear localization of ECT2-F in interphase cells may be at-
tributed to nuclear localization signals located in the cen-
tral region of ECT2 (Fig. 1 a).
 
Expression of ECT2 NH
 
2
 
-Terminal Domain
Inhibits Cytokinesis
 
The dynamic change of subcellular localization and G2/M-
specific modification of ECT2 suggest a possible role of
ECT2 in cell division. If ECT2 controls cell division
through the regulation of Rho GTPases, expression of
ECT2 mutants containing the domain that is required for
localization, but lacking the catalytic domain, may induce
a dominant negative phenotype. Therefore, we closely ex-
amined the morphology of cells expressing ECT2-N. Sur-
prisingly, 
 
z
 
60% of cells expressing ECT2-N became
multinucleated, with most cells containing two nuclei 72 h
after transfection (Fig. 3 B). Division of ECT2-N–express-
ing cells appeared to proceed to a stage just before the
separation of two daughter cells with single nuclei (Fig. 3
A, panels c and e), suggesting that a very last step of cyto-
kinesis was inhibited by ECT2-N expression. In contrast,
cells expressing ECT2-F, ECT2-C, or GFP expression vec-
tor alone did not exhibit such phenotypes. Since most of
the cells expressing ECT2-N underwent normal nuclear
division (Fig. 3 A, panels d and f), it is unlikely that these
multinucleated cells were generated as a consequence
of aberrant nuclear division. These results suggest that
ECT2-N can function as a dominant negative mutant to in-
hibit cytokinesis.
 
Microinjection of Anti-ECT2 Antibodies Specifically 
Inhibits Cytokinesis
 
To further examine the involvement of ECT2 in cytokine-
sis, we inhibited ECT2 function by microinjection of af-
finity-purified anti-ECT2 antibodies into asynchronously
growing HeLa cells (Fig. 4). Whereas cells injected with
control IgG divided normally, 
 
z
 
60% of cells injected with
anti–ECT2-DH, which recognizes the catalytic domain of
ECT2, became larger with double nuclei 24 h after injec-
tion. Since 25% of the injected cells had not divided at this
stage, 
 
z
 
80% of the cells were multinucleated upon com-
pletion of mitosis. After 48 h, 29% of anti–ECT2-DH–
injected cells contained three or four nuclei. The presence
of cells with more than two nuclei may indicate inhibition
of multiple rounds of cytokinesis with anti–ECT2-DH. In
contrast, very few control IgG-injected cells were multinu-
cleated. To rule out the possibility that anti-ECT2 cross-
Figure 2. Subcellular localization of ECT2 in interphase and mitotic cells. Endogenous ECT2 in HeLa cells was detected by affinity-
purified anti-ECT2 antibodies (green). Tubulin (red) and DNA (blue) were also stained with anti–b-tubulin antibody and 49,6-diami-
dino-29-phenylindole (DAPI), respectively. Merged images are also shown at the bottom, where colocalization of ECT2 and tubulin re-
sults in yellow color. a, interphase; b, prometaphase; c, metaphase; d, anaphase; e, telophase; f, cytokinesis. 
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reacted with other molecules that regulate cytokinesis, we
prepared a second affinity-purified antibody that specifi-
cally recognizes the NH
 
2
 
-terminal domain of ECT2. Mi-
croinjection of this antibody (anti–ECT2-N) also strongly
inhibited cytokinesis (Fig. 3 A, panels g–i; Fig. 3 B). These
results strongly suggest that ECT2 plays a critical role in
cytokinesis.
 
Discussion
 
The results from this study provide details about the bio-
chemical and biological functions of the 
 
ECT2
 
 protoonco-
gene product. We detected a mobility shift of ECT2 at
G2/M phases. Treatment of the ECT2 immunoprecipitates
with VHR dual specificity phosphatase resulted in shift
back of the band to the normal size. This strongly suggests
that ECT2 is modified by phosphorylation. We found that
dephosphorylation of ECT2 by phosphatases reduced the
exchange activity in vitro in a dose-dependent manner.
Therefore, ECT2 appears to be activated by phosphoryla-
tion, which occurs specifically in M phase. Since we could
not detect phosphorylated ECT2 with antiphosphoty-
rosine antibodies (our unpublished results), ECT2 may be
phosphorylated by serine/threonine kinases. Candidate
protein kinases that can activate ECT2 may include Cdc2-
regulated kinases and Cdc2 itself. The predicted amino
acid sequence of ECT2 contains two consensus Cdc2 phos-
phorylation sites (amino acids 327–330 and 814–817).
Further studies on ECT2 phosphorylation, including deter-
mination of phosphorylation sites and generation of phos-
phorylation-deficient mutants, will clarify the activation
mechanisms of ECT2.
Rho proteins were found to regulate actin polymeriza-
tion in studies on cytoskeletal organization of fibroblasts
Figure 3. Effects of a domi-
nant negative mutant of
ECT2 on cytokinesis. (A)
Subcellular localization of ex-
ogenously expressed ECT2
protein. The full-length
(ECT2-F; panels a and b),
NH2-terminal half (ECT2-N;
panels c–f), or COOH-termi-
nal half (ECT2-C; panels g
and h) of ECT2 was tran-
siently expressed in U2OS
cells as a GFP-fused protein.
GFP fusion proteins were de-
tected by green fluorescence
(panels a, c, e, and g). DNA
was stained with DAPI (pan-
els b, d, f, and h). (B) The
NH2-terminal domain of
ECT2 acts as a dominant
negative mutant for cytokine-
sis. Cells were transfected
with GFP-fused ECT2-F,
ECT2-N, or ECT2-C, or GFP
vector alone. GFP-expressed
cells are visualized by green
fluorescence (panels a and c).
DNA was stained with DAPI
(panels b and d). Arrow-
heads indicate multinucle-
ated cells. Bars, 20 mm.
(Right panel) GFP-express-
ing multinucleated cells were
scored under immunofluores-
cent microscopy 72 h after
transfection. Data are aver-
age of three independent ex-
periments. 
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(Hall, 1998). During cytokinesis in animal cells, an actin-
based contractile ring divides the cell into two daughter
cells. We found that ECT2 catalyzes nucleotide exchange
on Rho proteins and this activity appears to be dependent
on G2/M phase-specific phosphorylation. ECT2 was re-
leased to the cytoplasm after the nuclear membrane
breakdown and then accumulated in the midbody during
cytokinesis. Since ECT2-N localized in the midbody, but
ECT2-C did not, ECT2-N appears to determine the mid-
body localization of ECT2. We found that expression of
ECT2-N strongly inhibited cytokinesis. Because ECT2-N
localizes in the midbody but cannot catalyze nucleotide
exchange, it appears to function as a dominant negative
mutant. Moreover, microinjection of affinity-purified anti-
ECT2 antibody also inhibited cytokinesis. Therefore,
ECT2 might play an important role in cytokinesis. The nu-
clear localization of ECT2 may suggest another role of
ECT2 in mitosis. This possibility is under investigation.
However, the inhibition of cytokinesis with ECT2-N or
anti-ECT2 might not be attributed to the inhibition of mi-
tosis, because ECT2-N, which lacks nuclear localization
signals, was expressed in the cytoplasm and anti-ECT2 was
injected into the cytoplasm.
The presence of cell cycle regulator-related domains
and G2/M phase-specific phosphorylation of ECT2 sug-
gest the regulation of ECT2 activity by cell cycle machin-
ery. Therefore, ECT2 might be an important molecule
linking cell cycle machinery to Rho signaling pathways in-
volved in the regulation of cytokinesis. In 
 
Xenopus
 
, multi-
ple Rho proteins are involved in cytokinesis: whereas local
activation of Rho is important for proper constriction of
the contractile furrow, Cdc42 plays a role in furrow ingres-
sion (Drechsel et al., 1997). In 
 
Drosophila
 
, cytokinesis is
developmentally controlled during embryogenesis and is
omitted during the initial nuclear division cycles. It starts
in somatic cells with mitosis 14, but is blocked with muta-
tions in the 
 
pebble
 
 gene (Lehner, 1992). Recently, it was
reported that 
 
pebble
 
 encodes an ECT2-related protein,
which can interact with 
 
Drosophila
 
 Rho1 GTPase (Proko-
penko et al., 1999), suggesting that ECT2 is also involved
in cytokinesis in 
 
Drosophila
 
.
In mammalian cells, Rho GTPases also regulate cortical
actin remodeling (Hall, 1998). Inhibition of RhoA in nor-
mal rat kidney cells revealed that Rho regulates the com-
pletion of cytokinesis possibly through modulating the me-
chanical strength of the cortex (O’Connell et al., 1999).
Although the role of Rho in division of mammalian cells is
not well-documented, recently it was reported that two
Rho effectors, Rho-associated kinase and Citron kinase,
play a role in cytokinesis (Goto et al., 1998; Madaule et al.,
Figure 4. Inhibition of cytokinesis by microinjec-
tion of anti-ECT2 antibodies. (A) Affinity-puri-
fied anti-ECT2 antibodies specific to the NH2-
terminal domain (aECT2-N), or the DH domain
(aECT2-DH) were microinjected into unsyn-
chronized cultures of HeLa cells. Injected cells
were identified by immunostaining with anti–
rabbit IgG antibody (panels a, d, and g). Cells
were also stained for actin with phalloidine (pan-
els b, e, and h) and for DNA with DAPI (panels
c, f, and i) to determine the periphery of the cells
and morphology of nuclei, respectively. Panels
a–c show the morphology of cells injected with
control antibody, where two daughter cells were
observed. Microinjection of cells with aECT2-
DH (panels d–f) or aECT2-N (panels g–i) re-
sulted in single cells with two nuclei 24 h after in-
jection. Longer incubation (48 h) also resulted in
cells with more than three nuclei (data not
shown). Bars, 10 mm. (B) Number of single inter-
phase cells, normally divided cells, binucleated
cells, and multinucleated cells are shown 24 or
48 h after microinjection of the designated anti-
bodies. The last lane includes tri- and tetranucle-
ated cells. 
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1998). Further studies on ECT2, Rho GTPases, and their
effectors should clarify the signal transduction pathways
involved in the control of cell division.
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